Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 2a HERALD study of ALG-055009, a novel THR-beta agonist, showed significant reductions in liver fat at Week 12. This positive outcome was consistent across various subgroups, including patients using GLP-1 receptor agonists. The study specifically targeted non-cirrhotic MASH patients, highlighting its relevance in this population.
Price reaction · baseline $4.36 (2025-05-07 close) · hit after-hours · 5 other ALGS headline(s) in the window, move may be shared
day 0 close
+11.7%
day 1
+2.8%
day 3 · peak
+36.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Robust reductions in liver fat observed at Week 12.
  • Positive outcomes across subgroups including GLP-1 receptor agonist users.
  • Focus on non-cirrhotic MASH patients indicates targeted research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a novel thyroid hormone receptor beta (THR-beta) agonist.

What were the results of the HERALD study?

The study showed robust reductions in liver fat at Week 12.

Who were the participants in the study?

Participants included non-cirrhotic MASH patients and GLP-1 receptor agonist users.

What is the significance of the study's findings?

The findings indicate potential benefits of ALG-055009 for liver fat reduction.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare THR-beta agonist MASH Phase 2a study liver fat
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →